MBX Biosciences reports one-year Phase 2 extension data for once-weekly canvuparatide at ENDO 2026

MBX Biosciences

MBX Biosciences

MBX

0.00
  • MBX Biosciences scheduled a June 12, 2026 investor webcast to discuss once-weekly canvuparatide data ahead of ENDO 2026.
  • Results have not been presented yet; Phase 2 open-label extension findings are slated for June 12 at the Parathyroid Summit.
  • Full Phase 2 Avail trial results are set for an oral ENDO 2026 presentation on June 13.
  • The update highlights continued clinical progress for canvuparatide, supporting the program’s development path in endocrine disorders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729319) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.